Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.
about
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetesTumor necrosis factor alpha: a link between neuroinflammation and excitotoxicityThe genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control studyTumour Necrosis Factor Modulation for Treatment of Alzheimerʼs DiseaseTNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosisSelective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonismMeta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility lociThe intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the gamesPeptides identify multiple hotspots within the ligand binding domain of the TNF receptor 2Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesTranslational utility of experimental autoimmune encephalomyelitis: recent developmentsMonoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomesRole of T cell-glial cell interactions in creating and amplifying central nervous system inflammation and multiple sclerosis disease symptomsMultiple sclerosis-a quiet revolutionHumoral-targeted immunotherapies in multiple sclerosisInflammatory bowel disease: an increased risk factor for neurologic complicationsRole of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosisMonoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosisHistory of modern multiple sclerosis therapyAdalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the LiteratureMultiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!Relapsing-remitting central nervous system autoimmunity mediated by GFAP-specific CD8 T cells.New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.Neuroinflammation - using big data to inform clinical practice.On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.Role of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis.Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy.Modifiable factors influencing relapses and disability in multiple sclerosis.The role of chemokines in Guillain-Barré syndrome.Optic neuritis associated with adalimumab in the treatment of uveitis.Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.The pathogenesis of murine coronavirus infection of the central nervous system.The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.The role of TNFalpha and lymphotoxin in demyelinating disease.Tumor necrosis factor inhibitor-associated dermatomyositisMyelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case reportEtanercept in rheumatoid arthritis.
P2860
Q21134119-FDAB0DF4-5CFD-4467-A35C-9CC830494745Q21284512-AA7E3DAC-EF48-4B19-9084-8255448E7318Q21560832-CD41F48B-8B3F-466B-B604-595E8C18FFB0Q22241425-00F06E7D-387C-4404-A46F-BF368A3807DCQ24293476-84D38E25-15AA-4362-98F7-4580A5329DC0Q24652453-0D7629A7-E1D5-45E3-9878-94C9AA261451Q24656799-30069E0A-EC3D-4FCB-A968-5287514A0712Q24683018-2C726358-9507-42EA-BB9A-1826DC262614Q24804955-2EBC3602-D247-4BCD-81FF-4A75A98877F6Q24806367-D7A30A8D-C79C-4DCB-B3D5-8E469264131EQ26775820-A12BD874-C8DB-40C8-A907-C932E7EC88FCQ26776234-2B4BB461-1058-4549-AFD5-A07F0B3373EFQ26795528-A7AC1952-31F0-4879-93B9-A3A0927869C1Q26826930-296EF61C-6740-46C2-B173-E5756F27E420Q26865971-E0F3E97F-C498-4561-9E94-7440411BBE6EQ27690759-70CBAA7C-132D-421E-8D3C-14834F4B1DFDQ28082878-35C73BA4-1713-47E9-85CE-A7F0052C1367Q28144207-E9F5C09E-219C-432B-A374-2B7C2EB0E73BQ28273033-B46015B1-8F71-467E-81F6-17F4332106CDQ30047634-5E73C051-C021-4917-B25D-1374795370C9Q30571620-ABF33944-E88F-4E43-A5DD-58F43F10C2B3Q30574747-16044599-2B33-45C7-B617-0A7361C8E1EAQ30577403-99F903B5-617E-4A45-ACF2-8AA4D0D8347EQ30647378-F0B5D855-DFEB-4FEB-AA91-BE0A12362DF8Q30667754-94C38100-86F4-4B5D-9FF2-DEEBBE7532C4Q31142833-E4C14A60-2B62-44D1-860E-B9CA6A31AA4CQ33333935-A465AE6C-8488-4E8D-9613-F5F617C62AE1Q33352461-2A6E62E2-B60E-4AF2-93AF-C2691A5205FAQ33401933-CC57575E-2AF0-4C4B-B3F1-EF1EF56093F0Q33581753-B1563F08-2241-4324-82A8-EC6FFA5E2A55Q33624382-B67906C7-1B2B-49CC-B816-D0B48ADE1E03Q33681462-D6502B25-6C4C-4941-9061-5B4FF942CFA7Q33727962-C09C0A75-FCE0-4955-B2EE-9A1B589539C1Q33779927-93DEFDD2-F39E-452E-AD87-EC78D409035AQ33782327-802281CC-6DBA-4317-A9A7-B991416CA1B1Q33782397-4C207D3D-D343-48EC-A9A2-06D85CF2B41EQ34015824-658B0E9D-B663-425E-BE51-1F794B0EE7E9Q34023923-21BC7543-B1C3-4B2E-A308-CAAD98FACA6DQ34227269-5C4E6529-0466-4446-95D4-EC58ABF730B9Q34388601-A18788EC-4815-45F4-B663-EFE0246477B6
P2860
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Increased MRI activity and imm ...... necrosis factor antibody cA2.
@en
Increased MRI activity and imm ...... necrosis factor antibody cA2.
@nl
type
label
Increased MRI activity and imm ...... necrosis factor antibody cA2.
@en
Increased MRI activity and imm ...... necrosis factor antibody cA2.
@nl
prefLabel
Increased MRI activity and imm ...... necrosis factor antibody cA2.
@en
Increased MRI activity and imm ...... necrosis factor antibody cA2.
@nl
P2093
P921
P356
P1433
P1476
Increased MRI activity and imm ...... necrosis factor antibody cA2.
@en
P2093
Bertelsmann FW
Boringa JB
van Oosten BW
von Blomberg BM
P304
P356
10.1212/WNL.47.6.1531
P407
P577
1996-12-01T00:00:00Z